AstraZeneca therapy improves breast cancer survival in key trial
Drugmaker AstraZeneca on Wednesday said that its experimental breast cancer treatment improved patient survival without the ...
AstraZeneca’s Breast Cancer Drug Shows Positive Results In Late-Stage Trial
The drug candidate improved progression-free survival in patients, it said.
EU backs AstraZeneca, Daiichi's Enhertu for breast cancer treatment post endocrine therapy
The European Union's health regulator on Friday backed AstraZeneca and Daiichi Sankyo's drug Enhertu as a breast cancer ...
FierceBiotech6d
AstraZeneca, eyeing $5B peak sales, reports phase 3 breast cancer win for oral SERD
AstraZeneca has advanced its push to make camizestrant a blockbuster, reporting a phase 3 win for the oral SERD at an interim ...
GlobalData on MSN5d
AstraZeneca reports positive outcomes from breast cancer combo therapy trial
AstraZeneca has reported positive outcomes from a planned interim analysis of the double-blind Phase III SERENA-6 trial of ...
Breast Cancer Drugs Market Size is Projected to Reach USD 80.34 Billion by 2033, Growing at a CAGR of 8.90%: Straits Research
The global breast cancer drugs market size was valued at USD 34.25 billion in 2024 and is projected to reach from USD 37.30 ...
Pharm Exec8h
Follow-Up Results from OlympiA Trial Highlight 28% Mortality Benefit with Lynparza in gBRCAm Breast Cancer
Aliya Omer, VP, US franchise head, breast cancer, AstraZeneca, discusses how results of the trial compare with other treatments for gBRCAm HER2-negative high-risk early breast cancer.
BioSpace7h
AstraZeneca and Daiichi Sankyo’s Enhertu Enhances Stomach Cancer Case With Phase III Win
The partners are pushing to expand Enhertu’s list of indications beyond its standing uses in breast, lung and gastric cancers ...
BioSpace6d
AstraZeneca Posts Positive Phase III Results for Oral Breast Cancer Drug
In the Phase III SERENA-6 trial, camizestrant—in combination with CDK-inhibitors—beat out current standard-of-care treatments ...
FiercePharma1d
AstraZeneca, Daiichi unblind Enhertu study early as star ADC helps stomach cancer patients live longer
AstraZeneca and Daiichi Sankyo's Enhertu has become the first HER2-directed drug to mount a patient survival benefit in a ...
AstraZeneca therapy improves survival in late-stage breast cancer trial
Pharmaceuticals major AstraZeneca said on Wednesday that its experimental treatment, camizestrant, improved survival in ...
Reuters4d
EU backs AstraZeneca, Daiichi's Enhertu for breast cancer treatment post endocrine therapy
Feb 28 (Reuters) - The European Union's health regulator on Friday backed AstraZeneca (AZN.L), opens new tab and Daiichi Sankyo's (4568.T), opens new tab drug Enhertu as a breast cancer treatment ...